Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.68 -0.01 (-0.01%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

Bayer to Invest 5 Billion Euros in Weedkiller Research

Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Agilent Announces Receipt of FDA Approval for pharmDX Assay

Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.

Zachary Stutler headshot

3 Big Pharma Stocks to Buy Right Now

These big pharma stocks all have a Zacks Rank #2 or better.

Swarup Gupta headshot

Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout

The index traversed a volatile week, guided largely by trade-related developments.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.

Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

Here are five reasons why investors may consider betting on Merck (MRK) stock

Novartis Reports Data on Cosentyx for Psoriatic Arthritis

Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.

Kinjel Shah headshot

Boost Your Portfolio's Health With These 3 Big Drug Stocks

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

Merck (MRK) Gains But Lags Market: What You Should Know

In the latest trading session, Merck (MRK) closed at $82.48, marking a +0.02% move from the previous day.

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

The Zacks Analyst Blog Highlights: Microsoft, Cisco, Merck and Chevron

The Zacks Analyst Blog Highlights: Microsoft, Cisco, Merck and Chevron

AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

Kinjel Shah headshot

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Swarup Gupta headshot

Dow 30 Stock Roundup: UNH to Hike Dividend, MRK Zerbaxa's New Indication Gets FDA Nod

The index enjoyed a week of strong gains after the Fed Chair indicated that a near-term rate cut was increasingly likely.

Nalak Das headshot

5 Top Dow Stock Gainers of Past Month Still Holding Momentum

Despite severe market volatility, the blue-chip index of Wall Street has provided double-digit returns to investors so far this year.

Kinjel Shah headshot

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Neena Mishra headshot

Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference